Alejandro Ferrer

Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

Bile acid transporters and regulatory nuclear receptors in the liver and beyond

Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis

Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin

Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity

Biodistribution and function of extracellular miRNA-155 in mice

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

MicroRNAs in liver disease

Sensors and regulators of intracellular pH

Bicarbonate transport in cell physiology and disease

Molecular physiology and genetics of Na+-independent SLC4 anion exchangers

Ae2-Deficient Mice Develop Antimitochondrial Antibodies and Other Features Resembling Primary Biliary Cirrhosis